All articles tagged with #drc
With 100 days into the Bundibugyo Ebola outbreak, leaders say the response hinges on community leadership—survivors, women, health workers and local groups—working with authorities to find cases, trace contacts, vaccinate, and ensure safe burials; Uganda’s success shows the approach can work, but the next phase must reach villages with protected facilities, reliable funding, and strong cross-border coordination to stop transmission.
DRC’s Ebola outbreak has risen to 5,515 confirmed cases and 2,642 deaths (case fatality rate around 48%), with vaccine deliveries underway (16,250 doses arrived and 70,000 pledged) to tackle the Bundibugyo strain. Contact tracing improved to over 85%, but violence, displacement and attacks on health workers hinder containment. The WHO declared a Public Health Emergency of International Concern, and Pope Leo urged global and local action to save lives as the response scales up, even as global risk remains low and internal risk stays high.
During the Angelus, Pope Leo XIV urged the international community to mobilize aid and involve local communities to combat the Ebola outbreak in the Democratic Republic of Congo, which has claimed more than 2,500 lives out of about 5,300 cases amid conflict; he also prayed for the victims of a mining collapse in the Central African Republic.
The Democratic Republic of the Congo received 16,250 Ervebo vaccine doses in Kinshasa—the first batch of a 70,000-dose pledge—while the Bundibugyo strain circulating there has no approved vaccine; 20,000 doses will be used in a late-stage trial, with the remainder for frontline health workers. The outbreak has killed more than 2,500 people out of about 5,300 confirmed cases, and transmission is described as exponential, with containment hindered by ongoing conflict and weak infrastructure.
The Bundibugyo Ebola outbreak in the DRC has grown to 4,945 confirmed cases and 2,325 deaths, marking it the largest in the country’s history, with underreporting, distrust in authorities, and cash shortages hindering containment. About 850 known positives are unaccounted for, raising transmission risk, as authorities switch to door-to-door, village-based surveillance. Vaccines and treatments are advancing—Ervebo may offer cross-protection and Bundibugyo-specific vaccines are in safety trials—but funding gaps persist: $518m is needed for direct health response, yet only $264m has been disbursed. If funding and response don’t accelerate, the outbreak could surpass earlier records in coming months.
A Bundibugyo virus outbreak in DR Congo’s Ituri Province has become the deadliest Ebola outbreak in the country’s history, with over 4,900 confirmed cases and more than 2,300 deaths. The virus spread before official declaration on May 15, and there are no licensed vaccines or specific treatments for Bundibugyo, leaving containment to early detection, supportive care, infection prevention, and community engagement. Response is hampered by armed conflict, difficult access, and mistrust, though lab capacity in Ituri has expanded to aid case confirmation and surveillance.
The Democratic Republic of Congo’s Ebola outbreak has become the deadliest in the country’s history, with at least 2,325 deaths among 4,945 confirmed cases (101 new in the last 24 hours), predominantly in Ituri province as six of 26 provinces are affected. There are no approved vaccines or treatments for the Bundibugyo strain driving this surge, and the outbreak is the fastest-growing on record. In May, the WHO declared a public health emergency of international concern. Uganda has also reported cases, and transmission occurs via contact with infected bodily fluids and contaminated surfaces.
The Ebola outbreak in the Democratic Republic of the Congo has spread to Bas-Uele, the sixth province, with more than 2,100 deaths and 4,500 cases; the WHO cautions the outbreak could surpass the 2014–16 West Africa epidemic, noting the virus appears fast-moving and spreading beyond monitored contacts. There are no approved vaccines or treatments for Bundibugyo virus, and misinformation and unpaid health-worker strikes complicate response efforts. About 60–70% of new cases are outside monitored contacts, while two treatments are in clinical trials in Ituri as the outbreak—declared in May—likely began earlier, in February, and now affects six provinces.
A Nature Medicine study shows the current Ebola outbreak in the Democratic Republic of the Congo began with a new animal-to-human spillover of the Bundibugyo virus, then spread mainly through human-to-human transmission. With more than 4,400 cases and about 2,000 deaths, it’s the fastest-moving outbreak on record and could become the deadliest; there are no licensed vaccines or virus-specific treatments for this strain yet, though experimental options are in development. WHO projects the outbreak could peak within months and last up to a year under various scenarios, as efforts focus on expanded diagnostics, genomic sequencing, PPE for frontline workers, and cross-border measures amid challenges like health worker strikes and misinformation.
WHO Director-General Tedros Ghebreyesus warns the Democratic Republic of Congo Ebola outbreak is already the second-largest on record, spreading faster than any previous outbreak and on track to eclipse the West Africa epidemic of 2014–2016, with 4,449 confirmed cases and 2,061 deaths across five provinces; he notes many deaths occur in communities without treatment centers, stressing the need to trace and break every transmission chain as the Bundibugyo variant drives the surge.
The Bundibugyo strain of Ebola in eastern Congo has killed more than 2,000 people and infected over 4,300, with the strain being genetically distinct from the 2014 Zaire variant, limiting the effectiveness of existing therapies and vaccines. Despite the severity, the risk to Americans remains very low since transmission requires close contact with bodily fluids; researchers are pursuing new treatments and vaccines, including mRNA-based approaches, and international support is essential to containment.
More than 2,000 people have died and 4,381 cases have been confirmed in the Democratic Republic of Congo's Ebola outbreak, declared May 15, making it the second-largest on record and spreading faster than prior epidemics. The Bundibugyo strain, which lacks a vaccine, is amplified by diagnostic blind spots, fighting-access in a conflict zone, and weak contact tracing, with WHO officials saying the outbreak probably started in February.
DRC's Ebola outbreak has killed more than 2,000 people and infected 4,381 across five provinces—the fastest-growing outbreak in the country and the second-largest globally since 2014–16 West Africa—with response hampered by unpaid health workers, misinformation and traditional burials; there is no approved treatment or vaccine for the Bundibugyo strain yet, though vaccine trials are under way with results months away; the outbreak began in February and was declared in May, and a potential Ebola case in Israel linked to a traveler from the DRC is under investigation.
The Democratic Republic of Congo's Ebola outbreak—the fastest-growing on record—started in February, months before it was officially declared in mid-May. WHO sequencing suggests early cases were misattributed to malaria and typhoid. With 4,200 confirmed cases and at least 1,900 deaths, the Bundibugyo strain has no licensed vaccines or treatments, delaying response. WHO is pursuing Ervebo vaccine trials while Bundibugyo vaccines are in early development, amid challenges from strikes, conflict, misinformation, and displacement.
The Bundibugyo-strain Ebola outbreak in the Democratic Republic of the Congo has surpassed 4,000 confirmed cases and about 1,800 deaths. Africa CDC and WHO plan a scaled-up, door-to-door response, shifting from routine contact tracing to active case finding, with greater community engagement and use of antivirals and reconsideration of Ervebo vaccination. The outbreak spans multiple provinces, includes cross-border cases to Uganda, and health services are being disrupted as authorities intensify surveillance and response.